These finding were confirmed by hematoxylin and eosin (H&E) staining of the tumor sections after therapy, revealing a clear damage to tumors following systemic gene therapy with RGD4C.PDP-sTRAIL compared with non-targeted PDP-sTRAIL (Figure 7C). The gene discussed is PDP1; the disease is neoplasm.